...
首页> 外文期刊>Journal of Medicinal Chemistry >Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
【24h】

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

机译:(E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4)新型结合基元的优化,9-四氢-1H-吡啶并[3,4-b]吲哚-1-基)苯基)丙烯酸(AZD9496),一种有效且可口服的选择性雌激素受体下调剂和拮抗剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The discovery of an orally bioavailable selective estrogen receptor downregulator (SEED) with equivalent. potency and preclinical pharmacology to the intramuscular SEED fulvestrant is described. A directed screen identified the 1-aryl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole motif as a novel, druglike ER ligand. Aided by crystal structures of novel ligands bound to an ER construct, medicinal chemistry iterations led to (E)-343,5-difluoro-44(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido [3,4-b]-indol-1-yl)phenyl) acrylic acid (30b, AZD9496), a clinical candidate with high oral bioavailability across preclinical species that is currently being evaluated in phase I clinical trials for the treatment of advanced estrogen receptor (ER) positive breast cancer.
机译:等效的口服生物利用型选择性雌激素受体下调剂(SEED)的发现。描述了肌内SEED氟维司群的效价和临床前药理学。定向筛选确定了1-芳基-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚基序为新型的药物样ER配体。借助与ER构建体结合的新型配体的晶体结构,药物化学迭代产生了(E)-343,5-二氟-44(1R,3R)-2-(2-氟-2-甲基丙基)-3-甲基-2,3,4,9-四氢-1H-吡啶并[3,4-b]-吲哚-1-基)苯基)丙烯酸(30b,AZD9496)是临床前具有较高口服生物利用度的临床候选药物目前正在治疗晚期雌激素受体(ER)阳性乳腺癌的I期临床试验中进行评估。

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号